| abstract |
Ophthalmic compositions and associated method distinguished for the treatment of glaucoma and / or ocular hypertension in mammals, by topical administration into the eye of an ophthalmic composition containing, as active ingredient, one or more agonist compounds gamma-aminobutyric acid. The gamma-aminobutyric acid agonists used in the ophthalmic composition and the treatment process are, for example, gamma-aminobutyric acid (GABA), 5- (aminomethyl) -3 (2H) -isoxazolone (muscimol), 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol (THIP) and its pharmaceutically acceptable salt, piperidine-4-sulfonic acid and its pharmaceutically acceptable salt, 3- (2H ) -isothiazolone, 5- (aminomethyl) (thiomuscimol), 7-chloro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one (diazepam), 7 -chloro-1- [2- (diethylamino) ethyl] -5- (2-fluorophenyl) -1,3-dihydro-2H-1,4-benzodiazaepine-2-one (flurazepam) and its pharmaceutically acceptable salt, and the 7-chloro-N-methyl-5-phenyl-3H-1,4-benzodiazepin-2-amine 4-oxide, and its pharmaceutically acceptable salt. |